UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 50

Sortiert nach

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

The New England journal of medicine, 2016-07, Vol.375 (4), p.345-356

2016

Volltextzugriff (PDF)

Clinical Goals and Barriers to Effective Psoriasis Care

Dermatology and therapy, 2019-03, Vol.9 (1), p.5-18

2019

Volltextzugriff (PDF)

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial

JAMA dermatology (Chicago, Ill.), 2020-06, Vol.156 (6), p.649

2020

Volltextzugriff (PDF)

Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

JAMA dermatology (Chicago, Ill.), 2015-09, Vol.151 (9), p.961

2015

Volltextzugriff (PDF)

Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials

JAMA : the journal of the American Medical Association, 2011-08, Vol.306 (8), p.864

2011

Volltextzugriff (PDF)

Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis

Advances in therapy, 2022-05, Vol.39 (5), p.2256-2269

2022

Volltextzugriff (PDF)

Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS)

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2021-03, Vol.35 (2), p.229-238

2021

Volltextzugriff (PDF)

Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis

American journal of clinical dermatology, 2018-06, Vol.19 (3), p.437-447

2018

Volltextzugriff (PDF)

Serious adverse events-Missing in action: Comment on the article by Kremer et al

Arthritis & rheumatology (Hoboken, N.J.), 2012-09, Vol.64 (9), p.3055-3056

Leonardi, Craig L.

2012

Volltextzugriff (PDF)

Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLAR

Drug safety, 2021-06, Vol.44 (6), p.699-709

2021

Volltextzugriff (PDF)

Etanercept as Monotherapy in Patients with Psoriasis

The New England journal of medicine, 2003-11, Vol.349 (21), p.2014-2022

2003

Volltextzugriff (PDF)

Reduction in C-Reactive-Protein Levels With Adalimumab Therapy in Patients With Moderate-to-Severe Hand and/or Foot Psoriasis

Journal of drugs in dermatology, 2016-05, Vol.15 (5), p.562

2016

Volltextzugriff (PDF)

Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study

Journal of drugs in dermatology, 2013-08, Vol.12 (8), p.888

2013

Volltextzugriff (PDF)

Efalizumab in the treatment of psoriasis

Dermatologic therapy, 2004-10, Vol.17 (5), p.393-400

Leonardi, Craig L.

2004

Volltextzugriff (PDF)

Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting based on presentations by

The Journal of clinical and aesthetic dermatology, 2016-09, Vol.9 (9 Suppl 1), p.S5-S29

2016

Volltextzugriff (PDF)

Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis

Journal of drugs in dermatology, 2004-11, Vol.3 (6), p.614

2004

Volltextzugriff (PDF)

Persistent CD4+ T cell depression following combination alefacept and methotrexate therapy

International journal of dermatology, 2008-11, Vol.47 (11), p.1204-1206

2008

Volltextzugriff (PDF)

Introduction

Seminars in cutaneous medicine and surgery, 2014-06, Vol.33 (4 Suppl), p.S63-S63

Leonardi, Craig L

2014

Volltextzugriff (PDF)

A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1

Dermatology and therapy, 2012-12, Vol.2 (1), p.1-1, Article 1

2012

Volltextzugriff (PDF)

A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2

Dermatology and therapy, 2012-12, Vol.2 (1), p.2-2, Article 2

2012

Volltextzugriff (PDF)

Comparison of Tzanck smear, viral culture, and DNA diagnostic methods in detection of herpes simplex and varicella-zoster infection

JAMA : the journal of the American Medical Association, 1992-11, Vol.268 (18), p.2541

1992

Volltextzugriff (PDF)

Clinical efficacy of efalizumab in patients with chronic plaque psoriasis : Results from three randomized placebo-controlled. Phase III trials: Part I

Journal of cutaneous medicine and surgery, 2005-12, Vol.9 (6), p.303-312

2005

Volltextzugriff (PDF)

New and emerging therapies in psoriasis

Seminars in cutaneous medicine and surgery, 2014-03, Vol.33 (2 Suppl 2), p.S37-S41

2014

Volltextzugriff (PDF)

Development of Psoriasis Assessment Tools Among Patients in the CorEvitas Psoriasis Registry

Journal of psoriasis and psoriatic arthritis, 2023-04, Vol.8 (2), p.74-82

2023

Volltextzugriff (PDF)

A boxed warning for inadequate psoriasis treatment

Cutis (New York, N.Y.), 2016-09, Vol.98 (3), p.206-207

2016

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Aktive Filter

KollektionIngenta

KollektionTaylor & Francis:Master (3349 titles)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(32)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(30)
Science & Technology
(28)
Life Sciences & Biomedicine
(26)
Dermatology
(21)
Male
(19)
Female
(18)
Adult
(17)
Psoriasis - Drug Therapy
(17)
Biological And Medical Sciences
(15)
Medical Sciences
(15)
Psoriasis
(15)
Middle Aged
(14)
Severity Of Illness Index
(13)
Aged
(9)
Double-Blind Method
(9)
Treatment Outcome
(9)
Antibodies, Monoclonal - Therapeutic Use
(8)
Antibodies, Monoclonal - Administration & Dosage
(7)
General & Internal Medicine
(7)
Medicine, General & Internal
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

Clinical Goals and Barriers to Effective Psoriasis Care

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial

Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials

Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis

Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS)

Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis

Serious adverse events-Missing in action: Comment on the article by Kremer et al

Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLAR

Etanercept as Monotherapy in Patients with Psoriasis

Reduction in C-Reactive-Protein Levels With Adalimumab Therapy in Patients With Moderate-to-Severe Hand and/or Foot Psoriasis

Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study

Efalizumab in the treatment of psoriasis

Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting based on presentations by

Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis

Persistent CD4+ T cell depression following combination alefacept and methotrexate therapy

Introduction

A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1

A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2

Comparison of Tzanck smear, viral culture, and DNA diagnostic methods in detection of herpes simplex and varicella-zoster infection

Clinical efficacy of efalizumab in patients with chronic plaque psoriasis : Results from three randomized placebo-controlled. Phase III trials: Part I

New and emerging therapies in psoriasis

Development of Psoriasis Assessment Tools Among Patients in the CorEvitas Psoriasis Registry

A boxed warning for inadequate psoriasis treatment

Aktive Filter

Suchergebnisse filtern